SIGNAL Trial

Study Sponsor: Vaccinex Pharmaceuticals

Phase: Phase II, Safety and Efficacy

Clinical Sites in NC: Duke, Wake Forest

Website: http://huntingtonstudygroup.org/current-clinical-trials/signal-trial/

SIGNALThe SIGNAL trial is designed to assess the safety, tolerability, and effectiveness of VX15, a novel monoclonal antibody in people with late prodromal or early manifest Huntingtonā€™s disease (HD). This is a different class of drug than any other drug used in previous HD clinical trials. Monoclonal antibodies are more specific than most other drugs because